Click on a filter below to refine your search. Remove a filter to broaden your search.
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
In a fully adjusted model, greater adherence was linked to a reduced risk for cognitive impairment in women, but not in men.
The estimated percentage eligible ranges from 24 to 62% depending on the eligibility criteria used.
Wegovy, Zepbound and other cutting-edge weight-loss drugs are in short supply and often too expensive to afford without insurance coverage.
Over several years, lower all-cause mortality and major adverse cardiovascular events can be seen.
Once-weekly efsitora was noninferior to once-daily degludec for a decrease in the mean glycated hemoglobin level.
Black beneficiaries have lower average doses in the first 90 days.